Paul Baehr

Chairman & CEO, IBEX Technologies

Over 40 years pharmaceutical and related experience in healthcare and consumer product marketing. Currently, he is Chairman & CEO, IBEX Technologies, a manufacturer and marketer of proteins for biomedical use and arthritis assays widely used in osteoarthritis research.

Mr. Baehr began his career with Proctor & Gamble in product management. His career in pharmaceuticals began with CIBA-GEIGY where he served as Vice President & General Manager of the Pharmaceuticals Division, Canada, followed by Senior Vice President Marketing, CIBA-GEIGY US Pharmaceuticals Division. Subsequently, he joined Eastman Kodak as Corporate Vice President to head Kodak’s pharmaceutical diversification program culminating in the acquisition of Sterling Drug Inc. in New York then becoming Executive Vice President, Sterling-Winthrop Pharmaceuticals.

He has served on the board of the National Pharmaceutical Council in Washington, DC and a number of U.S. and Canadian biopharmaceutical companies. He also serves on the board of several hospitals including St. Barnabas Hospital in Livingston, N. J. and the Fox Chase Cancer Center in Philadelphia.

Mr. Baehr received his BA in Economics from the University of British Columbia, BC, Canada.

Michael E. Duffy, Esq.

Managing Partner, Duffy & Duffy, PLLC

Mr. Duffy has served as a director of our company since March 2019.  Mr. Duffy currently serves as the Managing Partner of the law firm, Duffy & Duffy, PLLC, is a highly experienced civil litigator with a passion for the law and a desire to represent victims of medical malpractice, where he has practiced since 1996. Mr. Duffy concentrates his practice on catastrophically injured victims and wrongful death claims involving medical malpractice and personal injury. Throughout his career, Mr. Duffy has been repeatedly named in Best Lawyers in America. Mr. Duffy received a J.D. from St. John's University and a Bachelor of Science degree in Business Administration from St. John's University. Mr. Duffy was admitted to the New York State Bar in 1995.

Carl Sailer

Global Client Solutions Executive, Syneos Health

Mr. Sailer’s career exceeds over 25 years as a commercial leader in the biopharmaceutical industry. He is currently a Global Client Solutions Executive for Syneos Health, a fully integrated biopharmaceutical solutions company which is expertised in taking new therapies to market, from clinical stage through commercial stage.  Mr. Sailer leads a global customer-centric commercial account team for the company's leading client valued at approximately $500M annually. Prior to Syneos Health, Mr. Sailer served as the Vice President of Sales and Marketing for Emisphere Technologies (2013-2019), Vice President of Commercial Operations at New American Therapeutics (2010-2012) and Akrimax Pharmaceuticals (2008-2010), in each case, where he built and led the commercial organizations for each start-up company.

Previously, Mr. Sailer was a member of the Executive Committee at PDI, a contract commercial organization, where he held several leadership positions in product commercialization and business development. Mr. Sailer started his career by holding various sales, marketing and sales management roles in the pharmaceutical and consumer products divisions of Bristol-Myers Squibb and Bayer Healthcare.

Mr. Sailer earned an MBA from Hofstra University, and a BS in marketing with a minor in journalism from Seton Hall University, where he currently serves on the Advisory Board of the Market Research Center at the Stillman School of Business.

John Terrana


John Terrana has over 20 years of experience in the pharmaceutical and biologic industries and currently serves as a regional sales and marketing manager at Glaxo SmithKline (Nasdaq: GSK) where he has worked for the past 19 years. Mr. Terrana has also invested in several other early stage private companies in the healthcare sector including investing in Dipexium Pharmaceuticals, Inc. (Nasdaq: DPRX) where he served as a member of the board of directors. Mr. Terrana received his Bachelor’s Degree in Engineering at Utica College of Syracuse University.

Mark Rathjen


Mark Rathjen serves as Managing Partner of Union Partner Advisors, a financial services company, where he has worked since November 2015 (Smithtown, NY).  From January 2015 to November 2015, Mr. Rathjen served as Managing Director, Healthcare Trader and Institutional Sales at BTG (NY, NY).  Prior to that, from April 2005 to December 2014, Mr. Rathjen served as Senior Managing Director, Head of Equity Trading and Sales Trading at Leerink Partners (NY, NY). Prior to that, Mr. Rathjen served as Vice President, Equity Trader, at Goldman Sachs (NYSE: GS), where he managed risk, price block trades, facilated corporate buybacks and served on the Technology Committee to develop new software, systems and applications among other duties.  Mr. Rathjen has invested in over two dozen pre-IPO biopharmaceutical, med-tech and technology companies and currently serves as the Treasurer for the Knox School.  Mr. Rathjen received his Bachelor’s Degree in Business from St. Bonaventure University.

Katie Jadhon


Katie Jadhon has experience investing in early stage companies in a variety of industries for over ten years, including participating in both debt and equity financing rounds for several pre-IPO technology and biopharmaceutical companies.  Ms. Jadhon received her Master’s Degree in Science Education from Cortland University.

John A. Jadhon, Esq


John Jadhon is a corporate lawyer whose practice primarily concentrates on corporate law, telecommunications law, and financial transactions. He has extensive experience handling mergers, acquisitions, and corporate financings. Mr. Jadhon represents both well-established companies and start-ups across a wide range of industries, including the biotechnology sector.

He also has extensive experience in investing in early stage companies including several within the biopharmaceutical sector. Mr. Jadhon is a graduate of Union College and Albany Law School.

Robert J. DeLuccia

Co-Founder & Managing Partner

  • Former Executive Chairman of Dipexium, a pharmaceutical company focused on Ph3 clinical development of an antimicrobial peptide for diabetic foot infection.
  • Responsibilities included all CMC, pre-clinical/clinical and regulatory activities, including direct liaison to FDA on all regulatory matters for multiple product candidates.
  • Over 45 years executive experience in the pharmaceutical industry involving sales, marketing, manufacturing and new product development with global pharmaceutical companies (Pfizer and Sanofi). Held senior executive positions in both companies and also CEO of two publicly (NASDAQ) traded biopharmaceutical companies (Immunomedics, Inc. and MacroChem CORP).
  • Areas of experience include new product introductions and drug development in the following areas: Antibiotics and antidiabetic agents: (amifloxacin, doxycycline, bacampicillin, cefaperazone, chlorpropamide and glypizide); Cardiovasculars: antiypertensive, heart failure, diagnostic contrast media, clopidogrel (antiplatelet agent).
  • Other: antianxiety/antidepression.
  • Topical new drug development areas include: creams/gels/liquids for erectile dysfunction, testosterone, onychomycosis and diabetic foot infection/wound care.
  • Lead Director of Board of Directors of IBEX Pharmaceuticals, a publicly-traded (IBT-TSX), Montreal-based company involved in the manufacture and marketing of proteins for biomedical use (Including Heparinase I for monitoring hemostasis in presence of anticoagulants). IBEX also manufactures arthritis assays, which are widely used in osteoarthritis research.
  • Mr. DeLuccia received his undergraduate and MBA degree from Iona College, N.Y..

David P. Luci, CPA, Esq.

Co-Founder & Managing Partner

  • Former CEO of Dipexium, a pharmaceutical company focused on Ph3 clinical development of an antimicrobial peptide for diabetic foot infection.
  • Responsibilities include capital raising efforts, investor relations, public relations, corporate development, business development, legal and finance activities more than seven years as CEO of Dipexium Pharmaceuticals in the antimicrobial/wound care area (Nasdaq: DPRX) as well as more than five years at Bioenvision (Nasdaq: BIVN) serving in roles as CFO, General Counsel and Executive Vice President.
  • Raised over $180 million in equity financing as CEO or CFO of 4 public and 2 non-public pharmaceutical companies including approximately $70 million as CEO of Dipexium.
  • Obtained analyst coverage by 9 Wall Street brokerage firms (3 firms at Dipexium; 6 firms at Bioenvision), including JP Morgan, UBS, CIBC, FBR, Raymond James, Feltl & Co. and Oppenheimer. Dipexium experience included three “Buy” or Strong Buy” recommendations.
  • Led 4 public offerings, including two IPO’s with two Nasdaq listings) and two secondary offerings (one Amex listing) in addition to 10 to 12 private equity offerings.
  • Led three in-licensing or out-licensing opportunities; negotiated the sale of Bioenvision (Nasdaq: BIVN) to Genzyme for $345 million and merger of Dipexium with PLx Pharma ($69 million).
  • Currently serves as Chairman of the Board of Directors of Ameri Holdings Inc. (Nasdaq: AMRH). Previously served on the Board of Directors of Abeona Therapeutics (Nasdaq: ABEO), PLx Pharma Inc. (Nasdaq: PLXP) and Dipexium Pharmaceuticals (Nasdaq: DPRX). Member, Steering Committee for the worldwide development of a leukemia drug with two members from Genzyme.
  • Mr. Luci is a CPA in the State of Pennsylvania (Inactive) and a corporate lawyer and is a graduate with a Bachelor of Science in Business Administration (Accounting) from Bucknell University and a J.D. (Cum Laude) from Albany Law School of Union University.